Stoke Therapeutics, Inc. STOK
24.80
(0.49)
(1.94%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow STOK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (61.10%) | (45.58%) | (2.37%) | 15.02% |
+8 more TTM periods Free account |
|
| (53.41%) | (39.94%) | (2.00%) | 12.41% | ||
ROIC |
(264.77%) | (225.55%) | (18.98%) | 28.42% | |
Return on Tangible Assets |
(72.84%) | (51.56%) | (2.74%) | 17.35% | |
Average Days of Receivables |
115.36 | 69.87 | 15.65 | 19.24 | |
Free Cash Flow per Share |
(2.74) | (2.34) | 0.76 | 0.89 | |
Free Cash Flow |
(180.68) | (147.69) | 44.92 | 52.37 | |
Capital Expenditures |
(2.69) | (0.87) | (0.67) | (0.48) | |
Piotroski F-Score |
2.00 | 2.00 | 4.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(27.88%) | (19.88%) | 7.15% | 9.50% | |
Accounts Receivable Turnover |
5.34 | 9.51 | 35.90 | 35.68 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
611.01% | 451.74% | 74.79% | 58.19% | |
Selling, General and Administrative Expense of Revenue |
298.68% | 225.71% | 36.38% | 28.59% | |
Share Based Compensation of Revenue |
135.72% | 106.73% | 17.48% | 14.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 0.86 | (6.62) | 1.30 | |
Depreciation/Fixed assets |
(0.03) | 0.21 | 0.20 | 0.17 | |
Capex/Depreciation |
17.26 | (1.20) | (1.05) | (0.91) | |
Revenue per Share |
0.42 | 0.51 | 3.11 | 3.51 | |
Operating CF per Share |
(2.70) | (2.33) | 0.77 | 0.90 | |
Capex per Share |
(0.04) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.10 | 0.03 | 0.00 | 0.00 | |
Net Profit Margin |
(753.60%) | (529.20%) | (3.73%) | 19.73% |
Columns are period end dates